Evidence map›Paper›PMID 34961526›Full record

ArticleJournal of neuroinflammation2021

A peripheral lipid sensor GPR120 remotely contributes to suppression of PGD

Kensuke Iwasa, Shinji Yamamoto, Kota Yamashina, Nan Yagishita-Kyo, Kei Maruyama, Takeo Awaji, Yoshinori Takei, Akira Hirasawa, Keisuke Yoshikawa

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Kensuke IwasaDepartment of Pharmacology, Faculty of Medicine, Saitama Medical University, 38 Moro-hongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Shinji YamamotoDepartment of Pharmacology, Faculty of Medicine, Saitama Medical University, 38 Moro-hongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Kota YamashinaDepartment of Pharmacology, Faculty of Medicine, Saitama Medical University, 38 Moro-hongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Nan Yagishita-KyoDepartment of Pharmacology, Faculty of Medicine, Saitama Medical University, 38 Moro-hongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Kei MaruyamaDepartment of Pharmacology, Faculty of Medicine, Saitama Medical University, 38 Moro-hongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Takeo AwajiDepartment of Pharmacology, Faculty of Medicine, Saitama Medical University, 38 Moro-hongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Yoshinori TakeiDepartment of Translational Research and Cellular Therapeutics, School of Medicine, Faculty of Medicine, Toho University, 5-21-16 Omori-Nishi, Ota-ku, Tokyo, 143-8540, Japan.
Akira HirasawaDepartment of Genomic Drug Discovery Science, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-Shimo-Adachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
Keisuke YoshikawaDepartment of Pharmacology, Faculty of Medicine, Saitama Medical University, 38 Moro-hongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan. keisukey@saitama-med.ac.jp.ORCID http://orcid.org/0000-0002-6348-6138
Saitama Medical University · JPKyoto University · JPSaitama Medical University Hospital · JPToho University · JP

Funding

Grant from Ochiai memorial award 2021ministry of education, culture, sports, science and technology 18K06899ministry of education, culture, sports, science and technology 18K07354ministry of education, culture, sports, science and technology 18K17933ministry of education, culture, sports, science and technology 25870677saitama medical university 17-B-1-23
6 · The paper itself

Abstract

backgroundNeuroinflammation is a key pathological component of neurodegenerative disease and is characterized by microglial activation and the secretion of proinflammatory mediators. We previously reported that a surge in prostaglandin D

methodsTo reveal the relationship between PGD

resultsIn the current study, we discovered notable neuroinflammation (increased PGD

conclusionsOur results suggest that neurological phenotypes in GPR120 KO mice are probably caused by dysfunction of intestinal GPR120. These observations raise the possibility that intestinal GLP-1 secretion, stimulated by intestinal GPR120, may remotely contributed to suppress PGD

Indexed as

AnimalsBehavior, AnimalFatty Acids, UnsaturatedGlucagon-Like Peptide 1HippocampusLiraglutideMaleMiceMice, Inbred C57BLMice, KnockoutMicrogliaNeurodegenerative DiseasesNeuroinflammatory DiseasesProstaglandin D2Receptors, G-Protein-CoupledSuppression, GeneticFatty Acids, UnsaturatedFFAR4 protein, mouseGlucagon-Like Peptide 1LiraglutideProstaglandin D2Receptors, G-Protein-CoupledG-protein-coupled receptor 120 (GPR120)NeuroinflammationProstaglandin

Identifiers

PMID34961526
PMCPMC8711188
OpenAlexW4200544786

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.